Literature DB >> 16511868

Time course of aquaporin expression after transient focal cerebral ischemia in mice.

Marlise de Castro Ribeiro1, Lorenz Hirt, Julien Bogousslavsky, Luca Regli, Jérôme Badaut.   

Abstract

Cerebral edema contributes to morbidity and mortality in stroke. Aquaporins (AQPs)-1, -4, and -9 have been identified as the three main water channels in the brain. To clarify their role in water movement, we have compared their expression patterns with brain swelling after transient focal brain ischemia. There were two peaks of maximal hemispheric swelling at 1 hr and at 48 hr after ischemia, coinciding with two peaks of AQP4 expression. At 1 hr after occlusion, AQP4 expression was significantly increased on astrocyte endfeet in the core and in the border of the lesion. At 48 hr, AQP4 expression was increased in astrocytes in the border of the lesion over the whole cell. AQP9 showed a significant induction at 24 hr that increased gradually with time, without correlation with the swelling. The expression of AQP1 remained unchanged. These results suggest that AQP4, but not AQP1 or AQP9, may play an important role in water movement associated with the pathophysiology of edema after transient cerebral ischemia in the mouse. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16511868     DOI: 10.1002/jnr.20819

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  81 in total

1.  Delayed increase of astrocytic aquaporin 4 after juvenile traumatic brain injury: possible role in edema resolution?

Authors:  A M Fukuda; V Pop; D Spagnoli; S Ashwal; A Obenaus; J Badaut
Journal:  Neuroscience       Date:  2012-06-21       Impact factor: 3.590

2.  Aquaporin-4 inhibition mediates piroxicam-induced neuroprotection against focal cerebral ischemia/reperfusion injury in rodents.

Authors:  Pallab Bhattacharya; Anand Kumar Pandey; Sudip Paul; Ranjana Patnaik; Dileep R Yavagal
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

3.  Brain water mobility decreases after astrocytic aquaporin-4 inhibition using RNA interference.

Authors:  Jérôme Badaut; Stephen Ashwal; Arash Adami; Beatriz Tone; Rebecca Recker; David Spagnoli; Béatrice Ternon; Andre Obenaus
Journal:  J Cereb Blood Flow Metab       Date:  2010-09-29       Impact factor: 6.200

Review 4.  Aquaporins in the brain: from aqueduct to "multi-duct".

Authors:  Jérôme Badaut; Jean-François Brunet; Luca Regli
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

Review 5.  Aquaporins in cerebrovascular disease: a target for treatment of brain edema?

Authors:  J Badaut; S Ashwal; A Obenaus
Journal:  Cerebrovasc Dis       Date:  2011-04-12       Impact factor: 2.762

Review 6.  Kidney-brain crosstalk in the acute and chronic setting.

Authors:  Renhua Lu; Matthew C Kiernan; Anne Murray; Mitchell H Rosner; Claudio Ronco
Journal:  Nat Rev Nephrol       Date:  2015-08-18       Impact factor: 28.314

7.  The protein kinase C activator phorbol myristate acetate decreases brain edema by aquaporin 4 downregulation after middle cerebral artery occlusion in the rat.

Authors:  Giovanna Fazzina; Angela M Amorini; Christina R Marmarou; Shinji Fukui; Kenji Okuno; Jana G Dunbar; Renee Glisson; Anthony Marmarou; Andrea Kleindienst
Journal:  J Neurotrauma       Date:  2010-02       Impact factor: 5.269

8.  The perivascular pool of aquaporin-4 mediates the effect of osmotherapy in postischemic cerebral edema.

Authors:  Emil Zeynalov; Chih-Hung Chen; Stanley C Froehner; Marvin E Adams; Ole Petter Ottersen; Mahmood Amiry-Moghaddam; Anish Bhardwaj
Journal:  Crit Care Med       Date:  2008-09       Impact factor: 7.598

9.  Aquaporin and vascular diseases.

Authors:  Carla Loreto; Ester Reggio
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

10.  Beneficial effect of agmatine on brain apoptosis, astrogliosis, and edema after rat transient cerebral ischemia.

Authors:  Che-Chuan Wang; Chung-Ching Chio; Ching-Hong Chang; Jinn-Rung Kuo; Ching-Ping Chang
Journal:  BMC Pharmacol       Date:  2010-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.